Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
This phase 2 trial investigated the efficacy of motesanib diphosphate, an orally active inhibitor of VEGF receptors, in patients with advanced differentiated thyroid cancer. None of the patients had had a response to conventional treatment. No patient had a complete response, but 14% had a partial response, with a median duration of 32 weeks. Motes...
Alternative Titles
Full title
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_223925199
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_223925199
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa075853
